Covalon Technologies Ltd. (TSXV: COV)

Market Cap	102.47M
Revenue (ttm)	29.20M
Net Income (ttm)	-823.40K
Shares Out	27.40M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,232
Open	3.830
Previous Close	3.740
Day's Range	3.720 - 3.870
52-Week Range	0.960 - 4.300
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 16, 2024

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by second...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Brent Ashton
• Employees: 37
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: COV

Financial Performance

In 2023, Covalon Technologies's revenue was 26.60 million, an increase of 46.56% compared to the previous year's 18.15 million. Losses were -4.46 million, -53.84% less than in 2022.